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Unfinished Business in Preventing
Alzheimer Disease
By law, the United States has a plan to address Alzheimer disease.1 The first of the National Alzheimer Project Act’s 5 goals is the discovery by 2025 of interventions that prevent and effectively treat the disease. The
eTable in the Supplement summarizes 5 current prevention trials, most supported jointly by the National Institutes of Health and pharmaceutical companies.2 This
alignment of public and private interests, shared resources, and the willingness of thousands of cognitively normal adults with heightened genetic or biomarker risk of Alzheimer disease to enroll in trials are
signs of progress. The plan is missing an important
strategy, however.
The aim of the medications being tested is to prevent, or significantly delay, the onset of symptomatic
Alzheimer disease. Only 1 of the 5 trials, however
(Generation; NCT02565511), uses measures of symptomatic disease or function as a coprimary end point. Instead, most use only a measure of cognition, called an
"intermediate clinical end point" because it does not
establish meaningful clinical benefit.3 The US Food and
Drug Administration’s (FDA) accelerated approval guidance, developed initially in response to public demand
to speed HIV treatments, permits this evaluation strategy for serious and life-threatening diseases, such as
Alzheimer disease.4 After approval, the expectation is
that evidence will be gathered to establish meaningful
clinical benefit.3 The national Alzheimer disease plan
lacks a strategy to decide what this evidence is and how
it should be gathered and interpreted.
A strategy for gathering and interpretating information is needed before the FDA approves a new drug
to prevent Alzheimer disease. After approval, the drug
will be marketed under a brand name, and public and
private interests and resources will begin to diverge.
Recent controversies over the cost of oncology medications show how private interests shape the evidence
that establishes that a medication has meaningful clinical benefit, and therefore its price.5
The Anti-Amyloid Treatment in Asymptomatic
Alzheimer Study (A4 Study; NCT02008357) offers a case
study. The A4 Study is testing whether 3 years of treatment with solanezumab, a drug designed to decrease
brain amyloid deposition and which is also being studied
in persons with mild–stage Alzheimer disease dementia,
slows the rate of cognitive decline in cognitively normal
adults ages 65 to 85 years who have evidence of elevated brain amyloid by positron emission tomography
scanning. The primary end point of the A4 Study is the
Alzheimer Disease Cooperative Study–Preclinical
Alzheimer Cognitive Composite (ADCS–PACC), a composite of 4 cognitive tests (2 measures of memory, a
measure of executive function, and the Mini-Mental State
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Exam [MMSE]). What if the trial shows that, compared
with placebo, persons on the study drug have slower cognitive decline? How is it established that this is a meaningful clinical benefit? At present, it is not known whether
a statistically significant difference in ADCS-PACC scores
between patients in different study groups would translate to a clinically meaningful improvement in current or
future ability to perform important cognitive tasks, such
as managing finances or taking medications.
Among chronic diseases of aging, Alzheimer disease is unique. About three-quarters of the economic
effect is related to the need for long-term daily care.6
Therefore, the benefit of a prevention therapy is shown
if it allows people to remain independent (ie, not demented) longer than if they did not take the treatment.
Studiesshouldtrackfunctionaloutcomessuchastheneed
for care (either as supervision or assistance) from family
or professionals at home or in a long-term care facility.
Answers to 3 questions will help to quantify these
outcomes: (1) Is there a slowing of the trajectory of cognitive decline after the onset of dementia? (2) Does treatment lead to a lengthening of the mild or severe stages
of dementia? (3) Does treatment delay death and, if so,
is treatment associated with compression or expansion of the time living with dementia?
A trial that measures 36 months of treatment cannot answer these questions because the outcomes that
establish the efficacy of a drug for preventing Alzheimer
disease—maintenance of independent function and decreased caregiving requirements—may not become apparent for considerably more than 3 years. Decision analytic models for the ADCS-PACC outcome can be used to
extrapolate effects on other outcomes in the treated
group vs the untreated group.7 Such models can provide
estimates of long-term treatment benefits under different assumptions about how the intermediate clinical end
point relates to clinical outcomes. Decision analytic models are not a substitute for clinical outcomes, however.
The participants in Alzheimer disease prevention
trials should continue to be followed in observational
cohort studies. Tracking functional outcomes (for
example, managing finances, medications, and driving), as well as scores on cognitive tests, should make it
easier to determine whether presymptomatic treatments actually prevent disability and dementia. It is also
important to study the relationships between cognitive
and clinical outcomes in patients who are more representative than those in clinical trials. This might be possible by adding the cognitive measures used in prevention trials to existing longitudinal cohorts, such as the
Medicare Current Beneficiary Survey, the Framingham
Heart Study, the Health and Retirement Study, and the
National Health and Aging Trends Study.

(Reprinted) JAMA Internal Medicine December 2016 Volume 176, Number 12

Copyright 2016 American Medical Association. All rights reserved.

Downloaded From: by a University of Pennsylvania User on 01/04/2018

1739

Opinion Viewpoint

The national strategy to establish the benefits of a treatment
to prevent Alzheimer disease should address 4 considerations.
First, the claim that such a treatment provides clinically meaningful
benefit will engage competing interests: the interest of the public—
patients, families, and public programs such as Medicare—who
want efficacious and affordable treatments and private, for-profit
interests of companies who own treatments and understandably
also want to maximize the return on their investments. The
National Alzheimer Project Act provides a public forum to assemble
these interests, prespecify approaches to interpret and weigh
evidence, and to make data and data analyses publicly available.
Second, older adults who receive therapies to prevent Alzheimer disease will typically have chronic diseases (eg, cardiovascular
disease) that increase their risk of both cognitive decline and death.
A treatment-related delay in the onset of dementia should occur before an individual is likely to die from another cause. Balancing the
benefits and risks of preventing dementia should include consideration of the competing risk of death from other causes.
Third, persons with Alzheimer disease are said to die twice, first
in mind and then in body years later. The judgment that a treatment
is valuable because patients lived longer should align with other values such as whether autonomy and quality of life are preserved. For
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Alzheimer disease, patient-reported measures of autonomy and quality of life are problematic. Even at the mild cognitive impairment stage,
patients often underreport the severity of functional losses.8 Information from spouses or adult children may be unavailable or of uncertain accuracy. Automated monitoring of financial tasks or driving
might detect the earliest symptoms, but software that monitors, aggregates,andanalyzesfinancialtransactionsordrivingbehaviorsraises
concerns about intrusions into privacy and independence and also
setting validated thresholds that justify intervention.
Fourth, patients may discontinue the medication. If discontinuation rates of Alzheimer prevention drugs are the same as for cardiovascular drugs (5% to 10% per year), the treatment benefit, if
there is one, is likely to decrease over time.9 The discontinuation rates
for investigational agents are not yet known; however, if they are
to prevent the onset of symptoms, they may need to be taken on a
regular basis for years.
Symptomatic Alzheimer disease is common, debilitating, and
costly. Although a national plan to prevent symptomatic disease can
address these problems, the plan needs an additional strategy to
show that expedited approval of new medications will truly
improve the lives of the millions of patients with asymptomatic
Alzheimer disease who may take them.

4. Approval based on a surrogate endpoint or on
an effect on a clinical endpoint other than survival
or irreversible morbidity. 21 CFR §314.510.
5. Neumann PJ, Cohen JT. Measuring the value of
prescription drugs. N Engl J Med. 2015;373(27):
2595-2597.
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